U.S. Antisense And Rnai Therapeutics Market Size & Outlook

The antisense and rnai therapeutics market in the United States is expected to reach a projected revenue of US$ 9,222.7 million by 2030. A compound annual growth rate of 18.8% is expected of the United States antisense and rnai therapeutics market from 2024 to 2030.
Revenue, 2023 (US$M)
$2,758.2
Forecast, 2030 (US$M)
$9,222.7
CAGR, 2024 - 2030
18.8%
Report Coverage
U.S.

U.S. antisense and rnai therapeutics market, 2018-2030 (US$M)

U.S.

Related Markets

U.S. antisense and rnai therapeutics market highlights

  • The U.S. antisense and rnai therapeutics market generated a revenue of USD 2,758.2 million in 2023 and is expected to reach USD 9,222.7 million by 2030.
  • The U.S. market is expected to grow at a CAGR of 18.8% from 2024 to 2030.
  • In terms of segment, antisense rna was the largest revenue generating technology in 2023.
  • RNA Interference is the most lucrative technology segment registering the fastest growth during the forecast period.


Antisense and rnai therapeutics market data book summary

Market revenue in 2023USD 2,758.2 million
Market revenue in 2030USD 9,222.7 million
Growth rate18.8% (CAGR from 2023 to 2030)
Largest segmentAntisense rna
Fastest growing segmentRNA Interference
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationRNA Interference, Antisense RNA
Key market players worldwideGSK PLC, Sanofi SA, Alnylam Pharmaceuticals Inc, Arbutus Biopharma Corp, Benitec Biopharma Inc, Silence Therapeutics PLC, Ionis Pharmaceuticals Inc, Sarepta Therapeutics Inc, Percheron Therapeutics Ltd


Other key industry trends

  • In terms of revenue, U.S. accounted for 62.9% of the global antisense and rnai therapeutics market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. antisense and rnai therapeutics market is projected to lead the regional market in terms of revenue in 2030.
  • Canada is the fastest growing regional market in North America and is projected to reach USD 242.5 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Antisense And RNAi Therapeutics Market Companies

Name Profile # Employees HQ Website

U.S. antisense and rnai therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antisense and rnai therapeutics market will help companies and investors design strategic landscapes.


Antisense rna was the largest segment with a revenue share of 70.4% in 2023. Horizon Databook has segmented the U.S. antisense and rnai therapeutics market based on rna interference, antisense rna covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to U.S. antisense and rnai therapeutics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of U.S. antisense and rnai therapeutics market databook

  • Our clientele includes a mix of antisense and rnai therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the U.S. antisense and rnai therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. antisense and rnai therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

U.S. antisense and rnai therapeutics market size, by technology, 2018-2030 (US$M)

U.S. Antisense And RNAi Therapeutics Market Outlook Share, 2023 & 2030 (US$M)

U.S. antisense and rnai therapeutics market size, by technology, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more